



Ref: FOIA Reference 2018/19-481

Date: 21st November 2018

Tel: 01782 676474
Email FOI@uhn.nhs.uk

Dear

I am writing in response to your email dated 8th November 2018 requesting information under the Freedom of Information Act (2000) regarding Metastatic Renal Cell Carcinoma.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Within your health Trust how many patients are currently [within the past 3 months] being treated with the following treatments for Metastatic Renal Cell Carcinoma;

If you do not treat, where do you refer these patients?

- **Axinitib**
- **Cabozantinib**
- **Everolimus**
- **Levantinib + Everolimus**
- **Nivolumab**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A1 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band some of the numbers, please see below:

Axinitib	Less than 5
Cabozantinib	Less than 5

Everolimus	0
Levatinib + Everolimus	0
Nivolumab	8
Nivolumab + Ipilimumab	0
Pazopanib	13
Sunitinib	9
Temsirolimus	0
Tivozanib	Less than 5
Other active systemic anti-cancer therapy	0
Palliative care only	This data is not held for patients on Best Supportive Care, as they are not on active SACT (Systemic Anti-Cancer Therapy)

**Q2 Within your health Trust how many patients are currently [within the past 3 months] being treated with the following treatments for Metastatic Melanoma:
If you do not treat, where do you refer these patients?**

**In the past 3 months, how many metastatic melanoma patients were treated with?
Of these how many were BRAF+**

- **Pembrolizumab**
- **Nivolumab**
- **Ipilimumab**
- **Nivolumab + Ipilimumab**
- **Dabrafenib + Trametinib**
- **Dabrafenib**
- **Vemurafenib**
- **Vemurafenib + cobimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A2 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band some of the numbers, please see below:

Pembrolizumab	17
Nivolumab	Less than 5
Ipilimumab	Less than 5
Nivolumab + Ipilimumab	6
Dabrafenib + Trametinib	13
Dabrafenib	Less than 5
Vemurafenib	0
Vemurafenib + cobimetinib	0
Other active systemic anti-cancer therapy	0
Palliative care only - data not held	This data is not held for

for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)	patients on Best Supportive Care, as they are not on active SACT (Systemic Anti-Cancer Therapy)
--	---

Q3 Within your health Trust how many patients are currently [within the past 3 months] being treated with the following treatments for metastatic colorectal cancer [mCRC];

If you do not treat, where do you refer these patients?

- **Cetuximab**
- **Aflibercept**
- **Bevacizumab**
- **Panitumumab**
- **Nivolumab**
- **Ramucirumab**
- **Regorafenib**
- **5FU only**
- **CAPIRI**
- **CAPOX**
- **5FU and FOLFI**
- **5FU and FOLFOX**
- **Oxaliplatin**
- **Irinotecan**
- **Tegafur Uracil + 5FU**
- **Other**

A3 Please see below:

Cetuximab	25
Aflibercept	0
Bevacizumab	0
Panitumumab	8
Nivolumab	0
Ramucirumab	0
Regorafenib	0
5FU only	0
CAPIRI	9
CAPOX	22
5FU and FOLFI	35
5FU and FOLFOX	16
Oxaliplatin	0
Irinotecan	0
Tegafur Uracil + 5FU	0
Other (Lonsurf)	6

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,



Leah Carlisle
Deputy Head of Quality, Safety & Compliance